Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders
Agomelatine (AGM) is one of the latest atypical antidepressants, prescribed exclusively for the treatment of depression in adults. AGM belongs to the pharmaceutical class of melatonin agonist and selective serotonin antagonist (“MASS”), as it acts both as a selective agonist of melatonin receptors M...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Brain Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3425/13/5/734 |